{"id":61622,"date":"2025-07-23T01:03:19","date_gmt":"2025-07-22T23:03:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/"},"modified":"2025-07-23T01:03:19","modified_gmt":"2025-07-22T23:03:19","slug":"medx-health-corp-names-john-gevisser-as-chief-executive-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/","title":{"rendered":"MedX Health Corp. Names John Gevisser as Chief Executive Officer"},"content":{"rendered":"
\n

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser<\/b> as the Company\u2019s Chief Executive Officer<\/b>, effective immediately.<\/p>\n

<\/a>
<\/a><\/p>\n

\nMr. Gevisser previously held the position of Chief Digital Officer<\/b> at Health Partners Group<\/b>, the United Kingdom\u2019s largest provider of occupational health services, where he led the company\u2019s technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX\u2019s UK pilot programs. Before that, he served as Vice President of Growth & Development<\/b> at Vitality Group<\/b> in the United States, where he was responsible for commercializing Vitality\u2019s direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world\u2019s largest wellness platform.<\/p>\n

\nAs MedX\u2019s CEO, Gevisser will focus on expanding MedX\u2019s international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities.<\/p>\n

\n\u201cJohn brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX\u2019s operations,\u201d said Mike Druhan, MedX President, Dermatology Services. \u201cHis ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.\u201d<\/p>\n

\n\u201cSkin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,\u201d said John Gevisser. \u201cAs a former client, I saw firsthand how seamlessly MedX\u2019s hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.\u201d<\/p>\n

\nWhile passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. \u201cThe Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,\u201d said Ken McKay, Chairman of the Board.<\/p>\n

\nAbout MedX Health Corp.<\/b><\/p>\n

\nMedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy\u00ae<\/sup> technology, integrated into the DermSecure\u00ae<\/sup> platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformit\u00e9 Europ\u00e9enne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX\u2019s advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy\u00ae<\/sup><\/b>, and its secure, cloud-based patient management system, DermSecure\u00ae<\/sup><\/b>. SIAscopy\u00ae<\/sup> is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin\u2019s surface. Visit: https:\/\/www.medxhealth.com<\/a><\/p>\n

\nNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/b><\/p>\n

\nThis Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.<\/i><\/b><\/p>\n

Contacts<\/b> <\/p>\n

\nMedX Health Corp.
\n
Mike Druhan, President, Dermatological Services
\n
mike.druhan@medxhealth.com<\/a>
(+1) 905-599-7852<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company\u2019s Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom\u2019s largest provider of occupational health services, where … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61622","6":"format-standard","7":"category-industry"},"yoast_head":"\nMedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company\u2019s Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom\u2019s largest provider of occupational health services, where ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T23:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MedX Health Corp. Names John Gevisser as Chief Executive Officer\",\"datePublished\":\"2025-07-22T23:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/\"},\"wordCount\":608,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250722152886\\\/en\\\/2530953\\\/22\\\/MedX_Logo.jpg.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/\",\"name\":\"MedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250722152886\\\/en\\\/2530953\\\/22\\\/MedX_Logo.jpg.jpg\",\"datePublished\":\"2025-07-22T23:03:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250722152886\\\/en\\\/2530953\\\/22\\\/MedX_Logo.jpg.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250722152886\\\/en\\\/2530953\\\/22\\\/MedX_Logo.jpg.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MedX Health Corp. Names John Gevisser as Chief Executive Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/","og_locale":"en_US","og_type":"article","og_title":"MedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend","og_description":"MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (\u201cMedX\u201d or the \u201cCompany\u201d) (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company\u2019s Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom\u2019s largest provider of occupational health services, where ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-22T23:03:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MedX Health Corp. Names John Gevisser as Chief Executive Officer","datePublished":"2025-07-22T23:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/"},"wordCount":608,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/","url":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/","name":"MedX Health Corp. Names John Gevisser as Chief Executive Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg","datePublished":"2025-07-22T23:03:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250722152886\/en\/2530953\/22\/MedX_Logo.jpg.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medx-health-corp-names-john-gevisser-as-chief-executive-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MedX Health Corp. Names John Gevisser as Chief Executive Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61622"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61622\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}